Orphan Drugs Market Research Report and Forecast 2020-2025

1. Global Orphan Drugs Market Research Report and Forecast 2020 - 2025 www.imarcgroup.com Sales@imarcgroup.com +1-631-791-1145

2. About IMARC WHO WE ARE? • We are a leading market research firm with expertise in market intelligence and business research • We deliver high quality, well- knitted, meaningful studies • We excel at understanding and synergizing with the business priorities of our partners and delivering tailored solutions WHAT DO WE DO? • Market research and business insights • Competitive intelligence and benchmarking • Strategy consulting • Consumer surveys and feedback analysis • Social and rural research • Market entry strategy • Syndicated Reports WHAT DO WE COVER? • Food And beverages • Dairy and dairy products • Agriculture and farming • Chemicals and materials • FMCG • Paper and packaging • Healthcare • Machinery, electronics and semiconductors WHO DO WE SERVE? • Collaborating with fortune 500 companies and SMEs • Serving all major clients from different industry which include Chemical & Materials, Food & Beverages, Packaging, Healthcare, Automotive, Heavy Industries, Retail, etc.

3. What We Do Competitive Intelligence and Benchmarking At IMARC, we help customers determine a competitor’s brand image and perception in the marketplace as compared to other key players. Cost Modeling and Cost Forecasting A good cost model supports organizations during negotiations to build strong relationships with suppliers. Cost modelling and price forecasting services from IMARC ensure clients make informed decisions. Market Research & Business Insights To develop deep customer understanding, we employ a range of quantitative and qualitative marketing research approaches along with big data techniques that are both innovative and pragmatic Country Entry Strategy IMARC team drafts and implement an optimum country entry strategy for expanding business in the country. Our team of consultants deeply evaluates and strategize the market opportunities for our clients and accentuate the business in congruence with Government regulations, exports and imports scenario, demand supply gap analysis and many more. Consumer Survey & Feedback Reports Consumer profiling, survey with end consumers, collection of their feedback and deep analysis. Based on the analysis, strategic decisions to enter in a new region, launch of new product, improvising the existing services Consumer Survey & Feedback Reports Competitive Intelligence and Benchmarking Cost Modeling and Cost Forecasting Market Research & Business Insights Country Entry Strategy

4. REPORT OBJECTIVES & Highlight

5. Report Description According to IMARC Group’s latest report, titled “Orphan Drugs Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025,”. Looking forward, IMARC Group expects the global orphan drugs market to exhibit moderate growth during the next five years. Orphan drugs are used to diagnose, prevent, and treat rare medical disorders. These drugs aim to meet particular public health requirements and generally have a limited production, only for a small group of patients. Orphan drugs help in treating several oncological, metabolic, hematologic, immunologic, infectious, and neurological ailments. These ailments majorly include lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, etc. Request for a free sample copy of this report: https://www.imarcgroup.com/orphan-drugs-market/requestsample Market Trends: The high prevalence of cancer and other rare genetic disorders is primarily driving the need for orphan drugs. Several pharma companies are focusing on developing new orphan drugs for providing personalized therapies for patients. Additionally, the higher approval rate of several pipeline drugs, along with the introduction of numerous favorable government policies to curb the spread of various infectious diseases, is also catalyzing the market growth. Moreover, extensive R&D activities for the development of biological orphan drugs that can treat cancer and minimize the damage caused to the stem cells are further expected to drive the market for orphan drugs in the coming years.

6. Report Description Orphan Drugs Market 2020-2025 Analysis and Segmentation: Competitive Landscape: The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market. • Some of these key players include: • AbbVie Inc. • Alexion Pharmaceuticals Inc. • Amgen Inc. • Biogen Inc. • Bristol-Myers Squibb Company • F. Hoffmann-La Roche AG (Roche Holding AG) • Jazz Pharmaceuticals Plc • Johnson & Johnson • Merck & Co. Inc. • Novartis AG • Pfizer Inc. • Sanofi S.A. • Takeda Pharmaceutical Company Limited • Teva Pharmaceutical Industries Ltd.

7. Report Description • The report has segmented the market on the basis of drug type, disease type, phase, top selling drug, distribution channel and region. • Breakup by Drug Type: • Biological • Non-Biological • Breakup by Disease Type: • Oncology • Hematology • Neurology • Cardiovascular • Others • Breakup by Phase: • Phase I • Phase II • Phase III • Phase IV

8. Report Description • Breakup by Top Selling Drugs: • Revlimid • Rituxan • Copaxone • Opdivo • Keytruda • Imbruvica • Avonex • Sensipar • Soliris • Others • Breakup by Distribution Channel: • Hospital Pharmacies • Retail Pharmacies • Online Stores • Others • Breakup by Region: • North America • United States • Canada • Asia Pacific • China

9. Report Description • • • • • • • • • • • • • • • • • • • Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa

10. Report Description • Key highlights of the report: • Market Performance (2014-2019) • Market Outlook (2020- 2025) • Porter’s Five Forces Analysis • Market Drivers and Success Factors • SWOT Analysis • Value Chain • Comprehensive mapping of the competitive landscape Explore full report with table of contents: https://www.imarcgroup.com/orphan-drugs-market If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization. Browse Related Report By IMARC Group Acne Drugs Market: https://www.imarcgroup.com/acne-drugs-market Regenerative Medicine Market: https://www.imarcgroup.com/regenerative-medicine-market

11. Report Description Key Questions Answered in This Report: •How has the global orphan drugs market performed so far and how will it perform in the coming years? •What has been the impact of COVID-19 on the global orphan drugs market? •What are the key regional markets? •What is the breakup of the market based on the drug type? •What is the breakup of the market based on the disease type? •What is the breakup of the market based on the phase? •What is the breakup of the market based on the top selling drugs? •What is the breakup of the market based on the distribution channel? •What are the various stages in the value chain of the industry? •What are the key driving factors and challenges in the industry? •What is the structure of the global orphan drugs market and who are the key players? •What is the degree of competition in the industry?

12. Table of Contents

13. Table of Contents 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Orphan Drugs Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Drug Type 6.1 Biological 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Non-Biological 6.2.1 Market Trends

14. Table of Contents 7 6.2.2 Market Forecast 7 Market Breakup by Disease Type 7.1 Oncology 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Hematology 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Neurology 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Cardiovascular 7.4.1 Market Trends 7.4.2 Market Forecast 7.5 Others 7.5.1 Market Trends 7.5.2 Market Forecast 8 Market Breakup by Phase 8.1 Phase I 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Phase II 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Phase III

15. Table of Contents 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Phase IV 8.4.1 Market Trends 8.4.2 Market Forecast 9 Market Breakup by Top Selling Drugs 9.1 Revlimid 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 Rituxan 9.2.1 Market Trends 9.2.2 Market Forecast 9.3 Copaxone 9.3.1 Market Trends 9.3.2 Market Forecast 9.4 Opdivo 9.4.1 Market Trends 9.4.2 Market Forecast 9.5 Keytruda 9.5.1 Market Trends 9.5.2 Market Forecast 9.6 Imbruvica 9.6.1 Market Trends 9.6.2 Market Forecast 9.7 Avonex 9.7.1 Market Trends

16. Table of Contents 9.7.2 Market Forecast 9.8 Sensipar 9.8.1 Market Trends 9.8.2 Market Forecast 9.9 Soliris 9.9.1 Market Trends 9.9.2 Market Forecast 9.10 Others 9.10.1 Market Trends 9.10.2 Market Forecast 10 Market Breakup by Distribution Channel 10.1 Hospital Pharmacy 10.1.1 Market Trends 10.1.2 Market Forecast 10.2 Retail Pharmacy 10.2.1 Market Trends 10.2.2 Market Forecast 10.3 Online Stores 10.3.1 Market Trends 10.3.2 Market Forecast 10.4 Others 10.4.1 Market Trends 10.4.2 Market Forecast 11 Market Breakup by Region 11.1 North America 11.1.1 United States

17. Table of Contents 11.1.1.1 Market Trends 11.1.1.2 Market Forecast 11.1.2 Canada 11.1.2.1 Market Trends 11.1.2.2 Market Forecast 11.2 Asia Pacific 11.2.1 China 11.2.1.1 Market Trends 11.2.1.2 Market Forecast 11.2.2 Japan 11.2.2.1 Market Trends 11.2.2.2 Market Forecast 11.2.3 India 11.2.3.1 Market Trends 11.2.3.2 Market Forecast 11.2.4 South Korea 11.2.4.1 Market Trends 11.2.4.2 Market Forecast 11.2.5 Australia 11.2.5.1 Market Trends 11.2.5.2 Market Forecast 11.2.6 Indonesia 11.2.6.1 Market Trends 11.2.6.2 Market Forecast 11.2.7 Others 11.2.7.1 Market Trends

18. Table of Contents 11.2.7.2 Market Forecast 11.3 Europe 11.3.1 Germany 11.3.1.1 Market Trends 11.3.1.2 Market Forecast 11.3.2 France 11.3.2.1 Market Trends 11.3.2.2 Market Forecast 11.3.3 United Kingdom 11.3.3.1 Market Trends 11.3.3.2 Market Forecast 11.3.4 Italy 11.3.4.1 Market Trends 11.3.4.2 Market Forecast 11.3.5 Spain 11.3.5.1 Market Trends 11.3.5.2 Market Forecast 11.3.6 Russia 11.3.6.1 Market Trends 11.3.6.2 Market Forecast 11.3.7 Others 11.3.7.1 Market Trends 11.3.7.2 Market Forecast 11.4 Latin America 11.4.1 Brazil 11.4.1.1 Market Trends

19. Table of Contents 11.4.1.2 Market Forecast 11.4.2 Mexico 11.4.2.1 Market Trends 11.4.2.2 Market Forecast 11.4.3 Others 11.4.3.1 Market Trends 11.4.3.2 Market Forecast 11.5 Middle East and Africa 11.5.1 Market Trends 11.5.2 Market Breakup by Country 11.5.3 Market Forecast 12 SWOT Analysis 12.1 Overview 12.2 Strengths 12.3 Weaknesses 12.4 Opportunities 12.5 Threats 13 Value Chain Analysis 14 Porters Five Forces Analysis 14.1 Overview 14.2 Bargaining Power of Buyers 14.3 Bargaining Power of Suppliers 14.4 Degree of Competition 14.5 Threat of New Entrants 14.6 Threat of Substitutes 15 Price Analysis

20. Table of Contents 16 Competitive Landscape 16.1 Market Structure 16.2 Key Players 16.3 Profiles of Key Players 16.3.1 AbbVie Inc. 16.3.1.1 Company Overview 16.3.1.2 Product Portfolio 16.3.1.3 Financials 16.3.1.4 SWOT Analysis 16.3.2 Alexion Pharmaceuticals Inc. 16.3.2.1 Company Overview 16.3.2.2 Product Portfolio 16.3.2.3 Financials 16.3.2.4 SWOT Analysis 16.3.3 Amgen Inc. 16.3.2.1 Company Overview 16.3.2.2 Product Portfolio 16.3.2.3 Financials 16.3.2.4 SWOT Analysis 16.3.4 Biogen Inc. 16.3.4.1 Company Overview 16.3.4.2 Product Portfolio 16.3.4.3 Financials 16.3.4.4 SWOT Analysis 16.3.5 Bristol Myers Squibb Company 16.3.5.1 Company Overview

21. Table of Contents 16.3.5.2 Product Portfolio 16.3.5.3 Financials 16.3.5.4 SWOT Analysis 16.3.6 F. Hoffmann-La Roche AG (Roche Holding AG) 16.3.6.1 Company Overview 16.3.6.2 Product Portfolio 16.3.6.3 SWOT Analysis 16.3.7 Jazz Pharmaceuticals Plc 16.3.7.1 Company Overview 16.3.7.2 Product Portfolio 16.3.7.3 Financials 16.3.7.4 SWOT Analysis 16.3.8 Johnson & Johnson 16.3.8.1 Company Overview 16.3.8.2 Product Portfolio 16.3.8.3 Financials 16.3.8.4 SWOT Analysis 16.3.9 Merck & Co. Inc. 16.3.9.1 Company Overview 16.3.9.2 Product Portfolio 16.3.9.3 Financials 16.3.9.4 SWOT Analysis 16.3.10 Novartis AG 16.3.10.1 Company Overview 16.3.10.2 Product Portfolio 16.3.10.3 Financials

22. Table of Contents 16.3.10.4 SWOT Analysis 16.3.11 Pfizer Inc. 16.3.11.1 Company Overview 16.3.11.2 Product Portfolio 16.3.11.3 Financials 16.3.11.4 SWOT Analysis 16.3.12 Sanofi S.A. 16.3.12.1 Company Overview 16.3.12.2 Product Portfolio 16.3.12.3 Financials 16.3.12.4 SWOT Analysis 16.3.13 Takeda Pharmaceutical Company Limited 16.3.13.1 Company Overview 16.3.13.2 Product Portfolio 16.3.13.3 Financials 16.3.13.4 SWOT Analysis 16.3.14 Teva Pharmaceutical Industries Ltd 16.3.14.1 Company Overview 16.3.14.2 Product Portfolio 16.3.14.3 Financials 16.3.14.4 SWOT Analysis

23. Report FAQs Team Profile Team Profile

24. Team Profile Growing team of 150+ employees with deep market knowledge Engineers and Post Graduates Account for 75% of our Team Post Graduates 30% Over 1000 Independent Consultants from different sectors Engineers 45% Talents from some of the top universities modelling specialists with unmatched expertise in quantitative research Individuals with experience in specific industries and having sound knowledge of targeted functional areas Non Engineering Graduates 15% Commercial and non-commercial relationships with some of the top research institutes Others 10%

25. Report FAQs Words From Client

26. Words From Client “We have been working with IMARC Group for over two years now. I must say that the word impossible doesn’t seems to appear in their dictionary,. These guys can provide data for any market in any country. I have been given them challenging assignments to work upon and have been quite impressed with their approach and results.” Procurement Technology Manager – Global FMCG Giant -Global “IMARC Group has great domain expertise and knowledge base provided all the inputs necessary for us to define the path forward and launch our diagnostic successfully in the market where other players were always afraid before investing.” -Vice President Marketing – European Diagnostic Company “We were really impressed with their research findings on the South India dairy market. The innovative idea suggested by them have given us altogether different aspect to look at the problem. We started with them on small project but now thinking on doing more strategic project with them.” -National Manager (Marketing) – Indian Diary Giant “IMARC Group helped us with the outsourcing of a major part of clinical trials to India. In the beginning we were skeptic of this idea. But the success achieved from this strategy is driving us to outsource other verticals of our business to low cost destinations” - Member of Board of Managing Director – Global Pharmaceutical Giant “Working with IMARC Group has been a great experience. They were able to provide us with a comprehensive business report on the India wastewater treatment market. The finding from the reports are played a major role in our business strategies and future decision making” -Senior Vice President – Major Indian Effluent Treatment Company

27. Report FAQs Report FAQs

28. Report FAQs 01 02 03 Do you provide market share information for a specific country/segment? Yes, we provide market share information and insights considering the scope. This service is provided as a part of customization requirements. My research requirement is very specific; can I customized the report? Yes, we provide customization of reports based on your requirements. It will be charged based on the scope of customization. Client have free access to pre-sales analyst briefs to discuss requirement and recommendations. How do you arrive at the market numbers? Our research methodology is a three cyclic process. It starts from information procurement from our inhouse database, primary research and secondary sources. The second step is data collection and analysis. The third step is data validation from industry experts, key players and other stakeholders. 04 05 I have a pre-defined budget. Can I buy chapters/sections of the report? We generally do not promote the sale of separate or individual segments from within a study, as it might fail to relay the actual meaning of the study or provide a holistic picture of the market. However, in special cases, select chapters are provided based on the client requirement. Do you offer post sales support? Yes, we offer post purchase analyst support for 4-6 weeks to our client in case they have any query within the scope of study.

29. Report FAQs 06 07 Who are your client? We have engaged 550+ clients across the globe. More than half of our client are re-engage us for additional reports and services How will I receive the report? The report in a PDF and Excel format will be sent to you electronically at your registered email address. Moreover, PPT and Word formats are also delivered to clients, on special requests. 08 09 How often does IMARC update studies? Research studies or reports are updated once in 6 months or a year depending on the traction & need. Please contact our sales team to inquire about a report update status. Will I have to pay for the post-sale customization needs? We offer our clients with a free 10% customization on the syndicated report. In case you have not availed this service as a pre-sale facility, we request you to share the requirements with our sales team. The research team post a feasibility will share the purview of the post-sale customization along with the price (if applicable) and the timeline.

30. SOME OF OUR KEY CUSTOMERS